Literature DB >> 24550356

Clusterin and complement activation in exfoliation glaucoma.

Ivo Doudevski1, Agueda Rostagno, Mary Cowman, Jeffrey Liebmann, Robert Ritch, Jorge Ghiso.   

Abstract

PURPOSE: The study was done to better understand the biological significance of clusterin co-localization with the exfoliation deposits (XF deposits), and provide insight into a pathogenic mechanism involving activation of the complement system and its pro-inflammatory consequences in patients with exfoliation glaucoma.
METHODS: Exfoliation lens deposits were analyzed by high resolution atomic force microscopy imaging and confocal immunofluorescence. Levels of clusterin and vitronectin, as well as of the complement activation products C3a and soluble C5b-9, were assessed via ELISA.
RESULTS: Atomic-force microscopy examination of lenses with exfoliation syndrome (XFS) revealed a dense fibrillar network on the anterior, aqueous-bathed surface of the lens, while the epithelial side displayed no discernible structural features at the same resolution. Clusterin colocalized with XF deposits, demonstrating integral association with the fibrils. Levels of activation-derived complement components C3a and soluble C5b-9, as well as the complement inhibitors clusterin and vitronectin, were found significantly elevated (1.7-fold, P < 0.05; 4.1-fold, P < 0.05; 1.8-fold, P < 0.01; and 3.0-fold, P < 0.01, respectively) in aqueous humor from glaucoma patients with XFS compared to non-XFS glaucoma controls.
CONCLUSIONS: The data provide compelling evidence for the activation of the complement system in XFS, highlighting the generation of subproducts with potent proinflammatory activity, which are capable of triggering and chronically maintaining levels of subclinical inflammation, suggesting novel targets for therapeutic intervention. The colocalization of clusterin in exfoliation fibrils suggests a failed attempt to prevent tissue accumulation of protein aggregates, as seen in other protein folding disorders, likely due to the abnormal high levels of misfolded proteins overwhelming its chaperone capacity.

Entities:  

Keywords:  complement system; exfoliation syndrome; extracellular chaperones; protein misfolding disorders

Mesh:

Substances:

Year:  2014        PMID: 24550356      PMCID: PMC3993868          DOI: 10.1167/iovs.13-12941

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  54 in total

1.  Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material.

Authors:  Matthias Zenkel; Friedrich E Kruse; Anselm G Jünemann; Gottfried O H Naumann; Ursula Schlötzer-Schrehardt
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  From molecules to cells: imaging soft samples with the atomic force microscope.

Authors:  M Radmacher; R W Tillamnn; M Fritz; H E Gaub
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

3.  Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study.

Authors:  T Hammer; U Schlötzer-Schrehardt; G O Naumann
Journal:  Arch Ophthalmol       Date:  2001-07

Review 4.  Chromosome 13 dementias.

Authors:  A Rostagno; Y Tomidokoro; T Lashley; D Ng; G Plant; J Holton; B Frangione; T Revesz; J Ghiso
Journal:  Cell Mol Life Sci       Date:  2005-08       Impact factor: 9.261

5.  Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls.

Authors:  S Fossati; J Cam; J Meyerson; E Mezhericher; I A Romero; P O Couraud; B B Weksler; J Ghiso; A Rostagno
Journal:  FASEB J       Date:  2009-09-21       Impact factor: 5.191

6.  Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study.

Authors:  C Cursiefen; T Hammer; M Küchle; G O Naumann; U Schlötzer-Schrehardt
Journal:  Acta Ophthalmol Scand       Date:  2001-10

7.  Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury.

Authors:  Vadim S Ten; Jun Yao; Veniamin Ratner; Sergey Sosunov; Deborah A Fraser; Marina Botto; Baalasubramanian Sivasankar; B Paul Morgan; Samuel Silverstein; Raymond Stark; Richard Polin; Susan J Vannucci; David Pinsky; Anatoly A Starkov
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

8.  Complement and complement regulatory proteins in human tears.

Authors:  M D Willcox; C A Morris; A Thakur; R A Sack; J Wickson; W Boey
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

Review 9.  Clusterin and Alzheimer's disease.

Authors:  Miguel Calero; Agueda Rostagno; Blas Frangione; Jorge Ghiso
Journal:  Subcell Biochem       Date:  2005

10.  Genetic analysis of the clusterin gene in pseudoexfoliation syndrome.

Authors:  Kathryn P Burdon; Shiwani Sharma; Alex W Hewitt; Amy E McMellon; Jie Jin Wang; David A Mackey; Paul Mitchell; Jamie E Craig
Journal:  Mol Vis       Date:  2008-09-22       Impact factor: 2.367

View more
  19 in total

Review 1.  Association of clusterin (CLU) variants and exfoliation syndrome: An analysis in two Caucasian studies and a meta-analysis.

Authors:  Bao J Fan; Louis R Pasquale; Jae H Kang; Hani Levkovitch-Verbin; Jonathan L Haines; Janey L Wiggs
Journal:  Exp Eye Res       Date:  2015-08-10       Impact factor: 3.467

Review 2.  Neuroinflammation in glaucoma: A new opportunity.

Authors:  Pete A Williams; Nick Marsh-Armstrong; Gareth R Howell
Journal:  Exp Eye Res       Date:  2017-02-24       Impact factor: 3.467

3.  Novel insight into the role of clusterin on intraocular pressure regulation by modifying actin polymerization and extracellular matrix remodeling in the trabecular meshwork.

Authors:  Avinash Soundararajan; Ting Wang; Sachin A Ghag; Min H Kang; Padmanabhan P Pattabiraman
Journal:  J Cell Physiol       Date:  2022-05-14       Impact factor: 6.513

Review 4.  Exfoliation Syndrome: A Disease of Autophagy and LOXL1 Proteopathy.

Authors:  Audrey M Bernstein; Robert Ritch; Jose M Wolosin
Journal:  J Glaucoma       Date:  2018-07       Impact factor: 2.503

Review 5.  A Role for Clusterin in Exfoliation Syndrome and Exfoliation Glaucoma?

Authors:  Janey L Wiggs; Jae Hee Kang; BaoJian Fan; Hani Levkovitch-Verbin; Louis R Pasquale
Journal:  J Glaucoma       Date:  2018-07       Impact factor: 2.503

6.  Lens capsule structure assessed with atomic force microscopy.

Authors:  Vivian M Sueiras; Vincent T Moy; Noël M Ziebarth
Journal:  Mol Vis       Date:  2015-03-15       Impact factor: 2.367

7.  GlyCAM1 negatively regulates monocyte entry into the optic nerve head and contributes to radiation-based protection in glaucoma.

Authors:  Pete A Williams; Catherine E Braine; Nicole E Foxworth; Kelly E Cochran; Simon W M John
Journal:  J Neuroinflammation       Date:  2017-04-26       Impact factor: 8.322

8.  Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan.

Authors:  Agueda Rostagno; Miguel Calero; Janice L Holton; Tamas Revesz; Tammaryn Lashley; Jorge Ghiso
Journal:  Neurobiol Dis       Date:  2021-07-21       Impact factor: 7.046

9.  Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma.

Authors:  Pete A Williams; James R Tribble; Keating W Pepper; Stephen D Cross; B Paul Morgan; James E Morgan; Simon W M John; Gareth R Howell
Journal:  Mol Neurodegener       Date:  2016-04-06       Impact factor: 14.195

10.  Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes.

Authors:  Mehdi Mirzaei; Veer B Gupta; Joel M Chick; Todd M Greco; Yunqi Wu; Nitin Chitranshi; Roshana Vander Wall; Eugene Hone; Liting Deng; Yogita Dheer; Mojdeh Abbasi; Mahdie Rezaeian; Nady Braidy; Yuyi You; Ghasem Hosseini Salekdeh; Paul A Haynes; Mark P Molloy; Ralph Martins; Ileana M Cristea; Steven P Gygi; Stuart L Graham; Vivek K Gupta
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.